The first stop for professional medicines advice

Medicines planning

61 results

Applied filters

Good governance when implementing ranibizumab biosimilar

29 June 2022Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance

Good governance when implementing natalizumab biosimilar

6 February 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.

Good governance when implementing eculizumab biosimilar

6 March 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring, and pharmacovigilance.

Delegation of roles under a PGD

19 March 2024Delegation of any PGD function is not permitted. However there are specific tasks that individuals other than the professional working under a PGD can fulfil.

Costing Clinical Trials of ATIMPs using the NIHR iCT - Advice for Pharmacy Sites

12 July 2022Guidance to support and promote consistent pharmacy costing for commercial clinical trials involving ATIMPs.

Considerations for developing national PGD templates

3 January 2024Decisions to develop PGD templates under the national Medicines Governance Do Once Programme depend on a variety of factors and advice on exclusions is given.

Biosimilars

Regularly updated material to support the introduction of adalimumab, eculizumab, natalizumab, ranibizumab, tocilizumab and ustekinumab biosimilars.

Biosimilar and key generic medicines - delivering better value

11 December 2024An overview of NHS England and NHS SPS roles in implementing biosimilar and key generic medicines and what to expect in 2025/26.

Authorising and preparing to use a PGD

30 July 2024Once a PGD is written, there are steps to be completed before the PGD is used within an organisation.
Registration required

Annual medicines planning publication, Prescribing Outlook

28 October 2022Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
admin